Diabetes

Fear of hypoglycemia (FOH) among youth and adolescents with type 1 diabetes (T1D) can lead to impaired sleep but may not negatively affect physical activity.

Knowledge gaps in basic management and diagnosis of type 1 diabetes (T1D) are present in newly graduated medical students, according to a recent study.

Andrew Lam, MD, retinal surgeon, author, assistant professor, University of Massachusetts Medical School discusses the earliest treatments for type 1 diabetes in children, a topic of his new book, "The Masters of Medicine: Our Greatest Triumphs in the Race to Cure Humanity’s Deadliest Diseases," due out April 18, 2023.

According to the study, maintaining modest residual beta cell function in newly diagnosed patients is associated with a lower risk of vascular complications and hypoglycemia. 

At the 44th National Association of Pediatric Nurse Practitioners Conference, a session presented data explaining why teenagers with type 1 diabetes were at high risk for developing anorexia and bulimia.

A supplemental New Drug Application for empagliflozin (Jardiance; Boehringer Ingelheim and Eli Lilly and Company) in pediatric patients with type 2 diabetes has been accepted by the FDA.

A systematic review of nearly 100 published studies provides an overview of sex-based disparities in the care of pediatric patients with type 1 diabetes.

A systematic review and meta-analysis of nearly 3 dozen published articles details the apparent increase in risk of cardiovascular disease and diabetes associated with a diagnosis of autism.

Recent research projects the prevalence of type 1 and type 2 diabetes among youths will rise through 2060.

In a recent study, it was found that obesity is not present in all cases of type 2 diabetes in pediatric patients.

A study found similar bone mineral density between children with and without type 1 diabetes.

Boehringer Ingelheim and Eli Lilly have announced positive results from a phase 3 trial for Jardiance in reducing blood sugar levels in children with type 2 diabetes.

The US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.

Elaine M. Apperson, MD, addresses early intervention and technologies for monitoring type 1 diabetes for disease management.

An expert pediatric endocrinologist discusses raising awareness among pediatricians about type 1 diabetes.

Dr Elaine M. Apperson provides insight on when to refer patients with type 1 diabetes to pediatric endocrinology and comments on offering sibling antibody screening.

Elaine M. Apperson, MD, reviews screening guidelines for the management of type 1 diabetes.

An expert pediatric endocrinologist addresses awareness of family history of type 1 diabetes as well as differentiating within type 1 and type 2 disease.

Dr Elaine M. Apperson defines each stage of type 1 diabetes and how progression may present in pediatric patients.

Elaine M. Apperson, MD, reviews the prevalence and risk factors in the pediatric population for type 1 diabetes.

An analysis of data from more than 9900 people with Down syndrome and 38,000 controls provides new insight into the apparent increase in risk of developing diabetes among children and young adults with Down syndrome.

In a recent presentation the NPWH 25th Annual Premier Women's Healthcare Conference, Jenny Madrid, MPH, RD, CDCES, BC-ADM, discussed medical nutrition therapy, a type of treatment plan for managing gestational diabetes by adjusting to an appropriate diet.

In a recent study, pediatric patients infected with COVID-19 were more likely to develop type 1 diabetes than those infected with other respiratory illnesses.

Results of the TARGET trial provide insight into the effects of tight glycemic targets versus less tight targets on maternal and perinatal outcomes among women with gestational diabetes.